Images of MTOR
An Interplay Between Autophagy and Immunometabolism for Host Defense Against Mycobacterial Infection
The many faces of mTOR and rapamycinBesides rapamycin itself, a number of other substances to varying degrees also inhibit mTOR signaling. Some of the newer substances are reported in publications such as (2008) A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis, (2008) Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability, (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTO and (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. Some of these alternative substances are selective in whether they affect mTORC1 or mTORC2. And they may vary also in toxicity and secondary effects.
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Experimental and Therapeutic Medicine PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review)